BRD4 Archives - Arvinas

Focus: BRD4

Small molecule PROTAC® hijacking and structural characterization of an E3 ligase, KLHDC2, for targeted protein degradation

The Arvinas PROTAC® Discovery Engine: PROTAC Biophysical Characterization Fuels The Discovery Of Target And E3 Ligase Ligands For Optimized PROTAC Degrader Molecules

IHC and flow cytometry quantifies BRD4 levels in surrogate tissues after ex-vivo and in-vivo dosing with a BRD4 degrading PROTAC®

BRD4 Proteolysis Targeting Chimera (PROTAC®) ARV-825, Causes Sustained Degradation of BRD4 and Modulation of Chemokine Receptors, Cell Adhesion and Metabolic Targets in Leukemia Resulting in Profound Anti-Leukemic Effects

BRD4 Degradation by PROTACs® Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in Ovarian Cancer

Hijacking Ubiquitin E3 Ligases Using PROTAC® Technology to Effectively Degrade BRD4 and Achieve Anti-tumor Efficacy

PROTAC® BRD4 Degraders Allow a More Effective Therapeutic Strategy than BRD4 Inhibitors

BRD4 Degradation by PROTACs® Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL

Hijacking the E3 Ubiquitin Ligase Cereblon to Efficiently Target BRD4

BRD4 Degraders Produce Long-Lasting Loss of BRD4 Protein and Robust Efficacy in Burkitt’s Lymphoma, Multiple Myeloma and Prostate Cancer Cells

;